Cédric Carrié1, Rachel Legeron2, Laurent Petit3, Julien Ollivier4, Vincent Cottenceau5, Nicolas d'Houdain6, Philippe Boyer7, Mélanie Lafitte8, Fabien Xuereb9, François Sztark10, Dominique Breilh11, Matthieu Biais12. 1. Anesthesiology and Critical Care Department, CHU Bordeaux, 33000 Bordeaux, France. Electronic address: cedric.carrie@chu-bordeaux.fr. 2. Pharmacy and Clinical Pharmacy Department, CHU Bordeaux, 33000 Bordeaux, France; Pharmacokinetics and PK/PD Group INSERM 1034, Univ. Bordeaux, 33000 Bordeaux, France. Electronic address: rachel.legeron@chu-bordeaux.fr. 3. Anesthesiology and Critical Care Department, CHU Bordeaux, 33000 Bordeaux, France. Electronic address: laurent.petit@chu-bordeaux.fr. 4. Pharmacy and Clinical Pharmacy Department, CHU Bordeaux, 33000 Bordeaux, France. Electronic address: julien.ollivier@chu-bordeaux.fr. 5. Anesthesiology and Critical Care Department, CHU Bordeaux, 33000 Bordeaux, France. Electronic address: vincent.cottenceau@chu-bordeaux.fr. 6. Pharmacy and Clinical Pharmacy Department, CHU Bordeaux, 33000 Bordeaux, France. Electronic address: nicolas.d'houdain@chu-bordeaux.fr. 7. Anesthesiology and Critical Care Department, CHU Bordeaux, 33000 Bordeaux, France. 8. Anesthesiology and Critical Care Department, CHU Bordeaux, 33000 Bordeaux, France. Electronic address: melanie.lafitte@chu-bordeaux.fr. 9. Pharmacy and Clinical Pharmacy Department, CHU Bordeaux, 33000 Bordeaux, France; Pharmacokinetics and PK/PD Group INSERM 1034, Univ. Bordeaux, 33000 Bordeaux, France. Electronic address: fabien.xuereb@chu-bordeaux.fr. 10. Anesthesiology and Critical Care Department, CHU Bordeaux, 33000 Bordeaux, France; Univ. Bordeaux Segalen, 33000 Bordeaux, France. Electronic address: francois.sztark@chu-bordeaux.fr. 11. Pharmacy and Clinical Pharmacy Department, CHU Bordeaux, 33000 Bordeaux, France; Pharmacokinetics and PK/PD Group INSERM 1034, Univ. Bordeaux, 33000 Bordeaux, France. Electronic address: dominique.breilh@chu-bordeaux.fr. 12. Anesthesiology and Critical Care Department, CHU Bordeaux, 33000 Bordeaux, France; Univ. Bordeaux Segalen, 33000 Bordeaux, France. Electronic address: matthieu.biais@chu-bordeaux.fr.
Abstract
PURPOSE: To determine whether augmented renal clearance (ARC) impacts negatively on piperacillin-tazobactam unbound concentrations in critically ill patients receiving 16 g/2 g/day administered continuously. MATERIAL AND METHODS: Fifty nine critically ill patients without renal impairment underwent 24-h creatinine clearance (CrCL) measurement and therapeutic drug monitoring during the first three days of antimicrobial therapy by piperacillin-tazobactam. The main outcome was the rate of piperacillin underexposure, defined by at least one of three samples under 16 mg/L. Monte Carlo simulation was performed to predict the distribution of piperacillin concentrations for various CrCL and minimal inhibitory concentration (MIC) values. RESULTS: The rate of piperacillin underexposure was 19%, significantly higher in ARC patients (0 vs. 31%, p = .003). A threshold of CrCL ≥ 170 mL/min had a sensitivity and specificity of 1 (95%CI: 0.79-1) and 0.69 (95%CI: 0.61-0.76) to predict piperacillin underexposure. In ARC patients, a 20 g/2.5 g/24 h PTZ dosing regimen was associated with the highest probability to reach the 16 mg/L empirical target, without risk of excessive dosing. CONCLUSIONS: When targeting a theoretical MIC at the upper limit of the susceptibility range, the desirable target (100%fT>16) may not be achieved in patients with CrCL ≥ 170 mL/min receiving PTZ 16 g/2 g/day administered continuously.
PURPOSE: To determine whether augmented renal clearance (ARC) impacts negatively on piperacillin-tazobactam unbound concentrations in critically illpatients receiving 16 g/2 g/day administered continuously. MATERIAL AND METHODS: Fifty nine critically illpatients without renal impairment underwent 24-h creatinine clearance (CrCL) measurement and therapeutic drug monitoring during the first three days of antimicrobial therapy by piperacillin-tazobactam. The main outcome was the rate of piperacillin underexposure, defined by at least one of three samples under 16 mg/L. Monte Carlo simulation was performed to predict the distribution of piperacillin concentrations for various CrCL and minimal inhibitory concentration (MIC) values. RESULTS: The rate of piperacillin underexposure was 19%, significantly higher in ARCpatients (0 vs. 31%, p = .003). A threshold of CrCL ≥ 170 mL/min had a sensitivity and specificity of 1 (95%CI: 0.79-1) and 0.69 (95%CI: 0.61-0.76) to predict piperacillin underexposure. In ARCpatients, a 20 g/2.5 g/24 h PTZ dosing regimen was associated with the highest probability to reach the 16 mg/L empirical target, without risk of excessive dosing. CONCLUSIONS: When targeting a theoretical MIC at the upper limit of the susceptibility range, the desirable target (100%fT>16) may not be achieved in patients with CrCL ≥ 170 mL/min receiving PTZ 16 g/2 g/day administered continuously.
Authors: Cristina Sanches; Geisa C S Alves; Andras Farkas; Samuel Dutra da Silva; Whocely Victor de Castro; Farah Maria Drummond Chequer; Francisco Beraldi-Magalhães; Igor Rafael Dos Santos Magalhães; André de Oliveira Baldoni; Mark D Chatfield; Jeffrey Lipman; Jason A Roberts; Suzanne L Parker Journal: Antibiotics (Basel) Date: 2022-03-24
Authors: Joan Antoni Schoenenberger-Arnaiz; Faten Ahmad-Diaz; Mar Miralbes-Torner; Ana Aragones-Eroles; Manuel Cano-Marron; Mercedes Palomar-Martinez Journal: Eur J Hosp Pharm Date: 2019-02-27
Authors: Roland N Dickerson; Christin N Crawford; Melissa K Tsiu; Cara E Bujanowski; Edward T Van Matre; Joseph M Swanson; Dina M Filiberto; Gayle Minard Journal: Nutrients Date: 2021-05-15 Impact factor: 5.717
Authors: Stefan Hagel; Friedhelm Bach; Thorsten Brenner; Hendrik Bracht; Alexander Brinkmann; Thorsten Annecke; Andreas Hohn; Markus Weigand; Guido Michels; Stefan Kluge; Axel Nierhaus; Dominik Jarczak; Christina König; Dirk Weismann; Otto Frey; Dominic Witzke; Carsten Müller; Michael Bauer; Michael Kiehntopf; Sophie Neugebauer; Thomas Lehmann; Jason A Roberts; Mathias W Pletz Journal: Intensive Care Med Date: 2022-02-01 Impact factor: 41.787